Literature DB >> 17213009

Measurable outcomes in psychiatric disorders: remission as a marker of wellness.

Roger S McIntyre1, Angelo Fallu, Jakub Z Konarski.   

Abstract

BACKGROUND: Mental disorders are highly prevalent, heterogeneous, and of multifactorial etiology. Collectively, they are associated with significant morbidity, mortality, and economic cost. Wellness is the optimal outcome in the management of chronic medical and psychiatric disorders.
OBJECTIVES: This review provides a synopsis of definitions and operational criteria for remission in major depressive disorder, bipolar disorder, schizophrenia, anxiety disorders, and attention-deficit/hyperactivity disorder (ADHD). The overall goals were to propose a treatment framework that gives primacy to therapeutic outcomes and to provide a rationale for psychiatry to quantify and measure patient outcome.
METHODS: Articles proposing definitions for remission were identified using a MEDLINE search (1966-April 2005) of the English-language literature (key terms: remission, anxiety disorders, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, and schizophrenia).
RESULTS: Operationalizing and quantifying critical end points in psychiatric disorders may help sharpen the focus of therapeutic activity and benefit patient outcome. In the absence of a validated biomarker of psychiatric illness activity, symptomatic remission and functional restoration are the only available markers of wellness in psychiatry. There is an emerging consensus regarding a definition for remission in major depressive disorder; several working definitions for bipolar disorder, schizophrenia, and anxiety disorders have been proposed. Developments in adult mood disorders-albeit incomplete-have been informative; managing psychiatric disorders that first appear in childhood (eg, ADHD) may also benefit by objectifying patient outcome.
CONCLUSIONS: Research is needed to determine the impact of applying a remission-focused model of illness management--emphasizing quantifiable, objective, and measurable end points--on overall patient outcomes.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17213009     DOI: 10.1016/j.clinthera.2006.11.007

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  6 in total

1.  Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study.

Authors:  D L Kelly; E Weiner; M P Ball; R P McMahon; W T Carpenter; R W Buchanan
Journal:  J Psychopharmacol       Date:  2008-06-26       Impact factor: 4.153

Review 2.  Surgical Management of Obesity Among People with Schizophrenia and Bipolar Disorder: a Systematic Review of Outcomes and Recommendations for Future Research.

Authors:  Youssef Kouidrat; Ali Amad; Brendon Stubbs; Suzan Moore; Fiona Gaughran
Journal:  Obes Surg       Date:  2017-07       Impact factor: 4.129

3.  Dopaminergic dysfunction and psychiatric symptoms in movement disorders: a 123I-FP-CIT SPECT study.

Authors:  Daniela Di Giuda; Giovanni Camardese; Anna Rita Bentivoglio; Fabrizio Cocciolillo; Arianna Guidubaldi; Lorella Pucci; Isabella Bruno; Luigi Janiri; Alessandro Giordano; Alfonso Fasano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-09-14       Impact factor: 9.236

4.  Higher order theory of mind in patients with bipolar disorder and schizophrenia/schizoaffective disorder.

Authors:  Guillem Navarra-Ventura; Muriel Vicent-Gil; Maria Serra-Blasco; Jesús Cobo; Sol Fernández-Gonzalo; Ximena Goldberg; Mercè Jodar; Josep Maria Crosas; Diego Palao; Guillermo Lahera; Eduard Vieta; Narcís Cardoner
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-05-04       Impact factor: 5.270

5.  Microstructural Changes of Anterior Corona Radiata in Bipolar Depression.

Authors:  I Fatih Karababa; Huseyin Bayazıt; Nihat Kılıçaslan; Mustafa Celik; Hasan Cece; Ekrem Karakas; Salih Selek
Journal:  Psychiatry Investig       Date:  2015-07-06       Impact factor: 2.505

6.  Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophrenia.

Authors:  Jun Ishigooka; Kazuyuki Nakagome; Tetsuro Ohmori; Nakao Iwata
Journal:  BMC Psychiatry       Date:  2013-10-03       Impact factor: 3.630

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.